Iridex Corporation receives European patent on MicroPulse technology

News
Article

According to the company, the patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields

The European Patent Office headquarters in Munich, Germany. Image credit: ©nmann77 – stock.adobe.com

The laser system is designed to minimise the risk of full-thickness retinal damage and vision loss. Image credit: ©nmann77 – stock.adobe.com

Iridex Corp today announced the award of the European Patent EP 3009093, titled "Laser System with Short Pulse Characteristics and its Methods of Use.”

According to a news release from the company, the patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields, for technology that enhances safe and effective laser treatments. Iridex is the exclusive provider of MicroPulse® devices that utilise the patented technology.1

"This advancement enhances both the safety and effectiveness of laser treatments in ophthalmology and the patent grant affirms our exclusive position as the only authorised provider of MicroPulse technology," David Bruce, president and CEO of Iridex, said in the news release.

According to the company, the technology delivers a laser system capability for delivering short, controlled-width pulse trains designed to minimise the risk of full-thickness retinal damage and vision loss, a common concern with traditional laser treatments with numerous clinical studies demonstrating its safety and efficacy in retina and glaucoma applications and beyond.

Moreover, by employing a diode pump source and a frequency-doubled solid-state visible laser, the system produces a pulsed output with controlled thermal effects, focusing on tissue-specific photoactivation without photocoagulation damage.1

The company also pointed out that its MicroPulse technology also incorporates software and hardware components in its feedback range control system, effectively managing energy fluctuations and enhancing safety during treatments. The technology covers the full laser wavelength range from 520 nm to 615 nm.

According to the news release the Unitary Patent will be enforced in European countries by members of the Unified Patent Court as well as the United Kingdom.

Reference

1. Iridex Corporation Receives European Patent on MicroPulse Technology. Iridex Corporation. Published February 6, 2024. Accessed February 6, 2024. https://www.globenewswire.com/news-release/2024/02/06/2824281/0/en/Iridex-Corporation-Receives-European-Patent-on-MicroPulse-Technology.htm
Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.